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Background: Endometrial adenocarcinomas are a rare type of tumour in cats. Though different morphologies have
been reported, the most frequent histological type of feline endometrial adenocarcinoma (FEA) is the papillary
serous. Characterization of molecular markers expression in FEA may contribute to clarify the pathogenesis of these
tumours and to assess the differences between normal endometrium and FEA regarding the expression pattern of
several proteins. Therefore, this study aimed to evaluate the immunohistochemical profile of a wide panel of
antibodies (specific for ER-α, PR, Ki-67, CK7 and CK20) in twenty-four cases of FEA. Comparisons were made
between FEA and feline normal cyclic endometrium in follicular (n = 13) and luteal (n = 10) stages. Except for Ki-67,
all other molecular markers were assessed independently for the intensity of immunolabeling and for the
percentage of cells expressing the protein.
Results: This study showed that in FEA a loss of expression occurs for ER-α (P ≤ 0.0001) and less markedly also for
PR. The lost in sex steroid receptors concerns a decrease in both the proportion of labelled cells and the intensity
of immunolabelling (P = 0.002 and P = 0.024, respectively). Proliferative activity, estimated via Ki-67 immunoreaction,
significantly increased in FEA as compared to normal endometrium (P ≤ 0.0001). Feline endometrial
adenocarcinomas maintained the CK7+/CK20+ status of normal endometrium. However, FEA showed decreased
CK7 intensity of labelling compared to normal endometria (P ≤ 0.0001) and loss of CK20 expression, both in
intensity (P≤ 0.0001) and in percentage of positive cells (P = 0.01), compared to normal tissues.
Conclusions: Data gathered in this study suggest that proliferation in FEA accompanies ER-α down-regulation,
possibly following activation of pathways mediated by local growth factors. Moreover, FEA retains combined
expression of CK7 and CK20, as evidenced in normal endometrial epithelia, although a decrease in CK7 expression
was observed.
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Endometrial adenocarcinomas are a rare type of tumour
in cats [1–3]. Uterine neoplasms account to 1 to 2 % of
the tumours affecting the queen’s reproductive organs,
representing 0.2 to 0.4 % of all feline tumours [4]. Never-
theless, in recent years an increasing number of reports
on feline endometrial adenocarcinomas (FEA) have been
published [5–9], suggesting that FEA may be more com-
mon than once believed.
Clinically, FEA are not distinguishable from other
non-neoplastic diseases of the cat uterus, like pyometra,
though they may have a completely different outcome,
particularly in older females [7, 10].
Knowledge on FEA is very restricted and mostly origi-
nated from case descriptions, complemented with a few
studies developed in a limited case series, supporting the
need for additional studies in larger case series [7, 11]. Im-
munohistochemistry is an acknowledged well-established
routine technique in anatomical pathology, very useful on
account of its easiness, safety and inexpensiveness com-
pared to other molecular techniques [12]. Moreover, locat-
ing a protein in tissue sections may be helpful to study
morphological characterization and potential behaviour of
tumours.
The cyclic interchange of estrogens and progesterone
secreted by the ovaries determines cyclic patterned
changes in the mammalian endometrium – the endomet-
rial cycle - with the ultimate goal of achieving a preg-
nancy. In the endometrium, major functions of circulating
sex steroids are dependent on the estrogen and progester-
one receptors (ER and PR). Particularly, these receptors
mediate the continuous synchronized epithelial-stromal
crosstalk that ultimately regulates the endometrial prolif-
eration, differentiation and secretion and thereby promote
embryo receptivity [13, 14]. In general terms, estrogen
stimulates the proliferation of glandular and stromal cells,
whereas progesterone inhibits the growth of glandular
cells and stimulates the secretory activity in the endomet-
rial glands. A disruption in the equilibrium of ER/PR [15],
or mutations in the genes coding these molecules [16],
may interfere with the normal proliferative or secretory
patterns, and predispose to endometrial disease. Estrogen
and progesterone receptors have been described in human
endometrial carcinomas as independent prognostic factors
[17]. Information on sex steroid receptors in feline endo-
metrium is scarce. Furthermore, in FEA, available data
concerning sex steroid receptors expression is limited and
frequently opposed. In general, loss of ER-α has been re-
ported, ranging from 50 % (4/8 cases) [18] to 83.3 % (5/6
cases) [11]; one study also refers that PR are generally
expressed in FEA [11]. This may raise an important con-
cern when sub-clinical FEA females are under progesta-
gen contraceptive treatment, which could interfere with
FEA progression and outcome. Moreover, the hormonereceptors status of FEA may adjoin important informa-
tion for medical management after ovariohysterectomy
(OVH) [11], deserving additional studies.
In general, cancer development and progression is as-
sociated with deregulation of cell proliferation and of
programmed cell death. The increased proliferative ac-
tivity in a tumour is related to its growth rate, and may
account for its malignancy and the clinical course of the
disease. Thus, its assessment yields useful prognostic in-
formation related to survival of patients in various types
of tumours [19]. Evaluation of the tumour proliferative
activity is frequently assessed by immunohistochemistry,
using the expression of Ki-67 nuclear antigen [20], a nu-
clear non-histone protein present exclusively in prolifer-
ating cells, whether they are normal or neoplastic [21].
Assessment of Ki-67 index has been applied to the nor-
mal endometrium, to characterize the cyclic changes in
cell proliferation in mares [22], cows [23] and bitches
[24]. Furthermore, the immunohistochemical profile of
Ki-67 has also been sporadically determined in feline
endometrial lesions, including in two FEA case reports
[8] - in which Ki-67 varied from moderate to high - and
in the description of multiple uterine lesions, which in-
cluded an area of endometrial adenocarcinoma, that ex-
hibited 40 % of positive cells for Ki-67 [25].
Cytokeratins (CK) are the largest group of intermediary
filaments proteins; they are essential in the development
and differentiation of epithelial cells. They are also crucial
for the normal structure and function of the epithelium,
as CK are involved in signal transduction, cell polarity and
gene regulation [26]; in addition, particular CK may also
contribute to the epithelial innate defence mechanisms,
through their antimicrobial properties [27]. Cytokeratins
are divided into two groups. Cytokeratin 20 is included in
the type I CK, which are acidic, low molecular weight
(40–56.5 kDa) proteins; whilst CK7 belongs to type II CK,
that consist of basic, high molecular weight (52–67 kDa)
proteins [28]. Different types of epithelia show specific
patterns of CK expression. In the uterus, CK are com-
monly found in the luminal and glandular epithelia [26]
and in the invading trophoblast [29, 30]. Antibodies raised
against CK are used as specific markers for epithelial cell
differentiation and are largely used for tumour identifica-
tion and classification [31]. The human uterine carcinoma
presents a CK7+/CK20- phenotype [26]. Espinosa de los
Monteros et al. (1999) strengthen the usefulness of the co-
ordinate expression of CK7 and CK20 to distinguish dif-
ferent primary feline carcinomas and to ascertain its
origin, in case of metastatic disease; they also described
the normal pattern of these CK in feline normal endomet-
rium [32]. Cytokeratin 7+/cytokeratin 20+ profiles were
described in 2/3 (66.7 %) FEA [32]. In another study, 3/6
(50.0 %) FEA expressed CK7, whereas 4/6 (66.7 %) FEA
showed positive reaction for CK20 [18].
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small number of cases, ranging from three [32] to six
[11] or eight [18], which might have contributed to the
reported contrasting results.
Therefore, the objectives of this study were: 1) to
evaluate the immunohistochemical expression of ER-α,
PR, Ki-67, CK7 and CK20 in the papillary serous form
of FEA using the largest case series reported so far; 2) to
monitor the changes in the immunoexpression of these
molecules as compared to the immunohistochemical
profile of feline normal endometrium in two different
stages of the estrous cycle; 3) to estimate putative associ-
ations between the molecular markers and the histo-
pathological predictors of dedifferentiation; 4) to study
the relationship between these markers.
Methods
Samples and animals
The study was conducted in twenty-four samples of FEA
retrieved from the archives of four different laboratories,
during a period of 8 years. As controls, twenty-three ar-
chived samples of histologically normal feline uteri were
selected (13 samples for the follicular stage – FS – and
10 samples for the luteal stage – LS). All samples were
previously fixed in 4 % neutral-buffered formalin and
routinely processed for paraffin embedding.
Control uterine samples were obtained after elective
ovariohysterectomy (OVH), from post-pubertal queens
aged seven months to eight years of age (mean 1.5 years).
Breed was unavailable in 65.3 % of the records; on the
other 34.7 % records, represented breeds included Domes-
tic Shorthaired cats (n = 7; 30.4 %) and Persian (n = 1;
4.3 %). For controls (normal endometria), only queens not
submitted to contraceptive treatment were selected.
Feline endometrial adenocarcinomas were diagnosed in
queens aged one year to 15 years of age (mean 7.9 years);
breeds included Domestic Shorthaired cats (n = 17; 70.8 %),
Siamese (n = 2; 8.3 %) and Persian (n = 1; 4.2 %). Contracep-
tion was given in five (20.8 %) animals and was denied in
three (12.5 %) FEA cases, though the length of treatment
was not mentioned in the form; no information existed in
the request form for the remainder 16 cases (66.7 %).
Regarding the clinical history of the animals diag-
nosed for FEA, data was collected from the histopatho-
logical request forms. The existence of clinical signs of
uterine disease was mentioned in 11 (45.8 %) cases,
whilst in six (25.0 %) other cases, the coexistence of
pyometra and a concurrent mammary tumour were re-
ferred. FEA was diagnosed in two (8.3 %) animals with-
out acknowledge clinical symptoms, the lesions in the
uterus being detected only during elective OVH as an
enlarged organ with increased consistency. For all the
other cases (n = 5; 20.8 %), the reasons for OVH were
not declared.Ethics statement
The study was approved by the Ethics Committee of
University of Trás-os-Montes and Alto Douro (Vila Real,
Portugal), permission number DOC22/CE/2014. None
of the animals was subjected to OVH purposely for the
present study.
Morphological evaluation
Feline endometrial adenocarcinomas diagnosis and the
staging of the cycle stage in normal samples of healthy en-
dometria (controls) were performed by light microscopy,
on three-micrometres sections routinely stained with
haematoxylin and eosin. The tumours were evaluated ac-
cording to several criteria of malignancy described in the
literature [18, 33, 34], enabling the diagnosis of FEA of the
papillary serous type [35]. The histopathological features
included: nuclear atypia, classified as low to moderate or
high; mean number of mitoses per high power field
(HPF), scored as lower than one, one to five and more
than five; and the existence of myometrium, serosa or vas-
cular/lymphatic invasion, evaluated as present or absent.
Normal uterine samples were staged as FS or LS based
on the summative information gathered by the ovarian
morphology (presence of follicles vs. corpora lutea), and
the histological endometrial features (the epithelial cell
height and the degree of development and coiling of
endometrial glands). For patients diagnosed with FEA,
determination of the stage of the estrous cycle was eval-
uated according to the presence of follicles in different
stages of development – FS – or the presence of corpora
lutea – LS – in the ovary.
For FEA cases, 11 cats (45.8 %) were in FS and seven
animals (25.0 %) were in the LS of the estrous cycle; on
the remaining cases (n = 7; 29.2 %), the surgical speci-
men did not include the ovaries thus impairing the sta-
ging of the estrous cycle.
Immunohistochemistry
Immunohistochemistry was performed in three-micrometre
sections by the indirect avidin-biotin peroxidase complex
technique. Table 1 summarizes the references of the anti-
bodies used in this study, their dilution and incubating
time. Antigen retrieval was performed in a steamer with
slides immersed in boiling citrate buffer (pH 6.0; about
94 °C) for 3 min. After cooling in phosphate buffered sa-
line (PBS), the sections were immersed in 3 % hydrogen
peroxide during 20 min to block endogenous peroxidase
activity. After the incubation with the normal serum for
5 min, the slides were incubated with the primary anti-
bodies (Table 1) for an overnight period, in a humid cham-
ber. Immunohistochemical labelling was achieved by
using the products specified in Table 1, following the man-
ufacturer’s instructions. Colour was developed with 3, 3-
diaminobenzidine tetrahydrochloride and sections were
Table 1 Primary antibodies used for immunohistochemistry
Antibody Clone Source Dilution Staining pattern Labelling
Monoclonal mouse anti-human
estrogen receptor (ER)




1A6 Novocastra®, UK 1:30
Monoclonal Mouse anti-human
Ki-67 Antigen
MIB-1 Dako®, Denmark 1:50
Clonal rabbit anti-human
Cytokeratin 7 (CK7)
R17-S DB Biotech®, Slovak Republic 1:100 Cytoplasm Lab Vision® UltraVision® Large Volume Detection
System, Thermo Fisher Scientific®, USA
Monoclonal mouse anti-human
Keratin 20 (CK20)
Ks 20.8 Thermo Fisher Scientific®, USA 1:100
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mounted for evaluation on light microscopy.
Quantification of immunolabelling
In normal endometrium, the immunolabelling for ER-α,
PR, Ki-67, CK7 and CK20 was evaluated independently
in the surface epithelium (SE), superficial and deep glan-
dular epithelium (SGE and DGE, respectively). In FEA
the immunostaining was assessed in epithelial tumour
cells. Stromal and myometrial labelling were evaluated
independently for ER-α and PR in both normal and neo-
plastic epithelium.
The intensity of ER-α and PR immunolabelling was
graded as 0 = no staining, 1 = weak, 2 =moderate and 3 =
strong. Regarding the percentage of cells expressing ER-
α and PR, the negative cut-off was established at 5 %
[12, 36–38]. Since the majority of the controls (n = 20/
23) had more than 80 % of positive cells, this was set-
tled as the maximum cut-off. Therefore, the samples
were further classified semiquantitatively according to
the marks: 0 = negative (≤5 % positive nuclei); 1 = loss
of expression (5 to 80 % positive nuclei) and 2 = posi-
tive (≥80 % positive nuclei).
The evaluation of Ki-67 immunostaining was per-
formed in 1000 cells in 10 HPF (x 400) and expressed as
a percentage – proliferative index [20].
The immunoexpression for CK7 and 20 was semi-
quantitatively scored for both the percentage of labelled
cells (1 to 33 % = low; 34 to 66 % =moderate; 67 to
100 % = high) and the labelling intensity (1 = weak; 2 =
moderate; 3 = strong) [32]. This evaluation was per-
formed for the entire endometrium section in controls
and in representative microscopic fields for FEA. The
labelling intensity was evaluated on the basis of the
most frequently observed.
Statistical analysis
For data concerning the sex steroids and CK immunola-
beling (categorical variables) the statistical comparisons
were performed by using chi-square and Fisher exacttests in the IBM SPSS Statistics Base 20.0 software®. Ki-67
data were analysed using the ANOVA test, the post hoc
paired comparisons were carried out using the Bonferroni




In the present study, FEA were primarily characterized
by the multi-layered proliferation of neoplastic endomet-
rial epithelial cells on papillae into the lumen supported
by a thin fibrovascular stroma. Tubular and solid prolif-
eration was scantly present. Therefore, tumours were
histologically classified as FEA of the papillary serous
type (Fig. 1). Neoplastic cells were pleomorphic colum-
nar shaped, with a moderate amount of eosinophilic
cytoplasm and round-to-oval, vesicular or hyperchro-
matic nuclei that lost the normal polarity. Numerous
multinucleated cells with darkened nuclei were present
within and at the surface of the lesions. A variable
number of clear cells - large, round to polygonal cells,
with foamy cytoplasm and eccentric, crenated or ovoid
nucleus – comprised less than 50 % of the tumours’
area. Nucleoli were evident; occasional intranuclear clear
inclusions were also found. Randomly distributed areas
of necrosis within the tumours were frequently present.
A variable degree of atypia was found in FEA lesions
(Table 2), with 54.2 % (13/24) of the cases evidencing
high atypia.
The mean number of mitoses per HPF in FEA was
higher, compared to normal epithelia (P ≤ 0.0001). In the
majority of FEA (n = 19; 79.2 %), the mean number of
mitoses per HPF was established between one and five,
with very few cases (n = 2; 8.3 %) presenting more than
five mitoses per HPF (Table 2), in contrast with the ob-
served in the normal endometrium. The SE always pre-
sented less than one mitosis per HPF, both whether the
FS and LS was considered (Table 2). The mean number
of mitoses per HPF in the glandular epithelia was more
variable, but the prevailing value was less than one for
Fig. 1 FEA. Papillary growth of high atypical epithelial tumour cells, invading uterine myometrium. Haematoxylin and eosin. BAR = 100 μm
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ples in FS and LS, respectively. The mean number of mi-
toses was similar in the DGE in the FS (92.3 %; 12/13),
but slightly lower in the LS (70.0 %; 7/10) (Table 2).
Myometrial invasion was observed in a large propor-
tion of cases (66.7 %; 16/24), while vascular invasion was
observed in only 12.5 % (3/24) of the cases; serosa im-
pairment was only detected in 4.2 % (1/24) FEA; though
vascular and serosa invasion occurred independently in
either situation myometrial invasion. In normal uterine
samples, as expected, the anatomical integrity of myo-
metrium and serosa layer was maintained.Immunohistochemistry
In the samples of normal endometrium, immunoreac-
tion against ER-α and PR was consistently detected forTable 2 Main histological features of feline endometrial adenocarcin
Atypia Number of mito




FS SE 13 (100.0) 0 0 13 (100.0) 0
SGE 13 (100.0) 0 0 12 (92.3) 1
DGE 13 (100.0) 0 0 12 (92.3) 1
LS SE 10 (100.0) 0 0 10 (100.0) 0
SGE 10 (100.0) 0 0 10 (100.0) 0
DGE 10 (100.0) 0 0 7 (70.0) 3
FEA 0 11 (45.8) 13 (54.2) 3 (12.5) 1
FS = follicular stage; LS = luteal stage; FEA = feline endometrial adenocarcinomas; SE
glandular epithelium; HPF = high power fieldall epithelial types, as well as for the stroma and myome-
trium (Table 3; Fig. 2 (a-b)).
The intensity of labelling against ER-α was, in general,
weaker in the SE than in the GE and the intensity scores
were higher in the DGE than in SGE. However, the dif-
ferences in the represented epithelia were significant for
LS, but not for FS (P = 0.011 and P = 0.593, respectively;
Table 3). The intensity of immunostaining for ER-α was
slightly lower in the SE and SGE during LS in comparison
to FS, but changes were more discrete regarding the DGE
intensity of immunostaining. A moderate to strong inten-
sity (scores 2 or 3) was evidenced in both the stroma and
the epithelial elements in the normal endometrium for
most samples (Table 3). A slight reduction was observed
in the ER-α intensity for the endometrial stroma (Table 3).
However, the stage of the cycle did not significantly affect







-5 ≥5 n (%) n (%) n (%)
0 0 0 0
(7.7) 0 0 0 0
(7.7) 0 0 0 0
0 0 0 0
0 0 0 0
(30.0) 0 0 0 0
9 (79.2) 2 (8.3) 16 (66.7) 1 (4.2) 3 (12.5)
= surface endometrium; SGE = superficial glandular epithelium; DGE = deep
Table 3 Results for the immunoexpression of the ER-α and PR in the normal feline uterus (at the FS and LS) and in the neoplastic
epithelium in FEA
Intensity Percentage of positive cells
n (%) n (%)
0 1 2 3 0 1 2
ER-α
FS SE 0 0 7 (53.8) 6 (46.2) 0 0 13 (100.0)
SGE 0 0 3 (23.1) 10 (76.9) 0 0 13 (100.0)
DGE 0 0 1 (7.7) 12 (92.3) 0 0 13 (100.0)
Stroma 0 0 4 (30.8) 9 (69.2) 0 7 (53.8) 6 (46.2)
Myometrium 0 0 12 (92.3) 1 (7.7) 0 0 13 (100.0)
LS SE 0 3 (30.0) 5 (50.0) 2 (20.0) 0 2 (20.0) 8 (80.0)
SGE 0 0 6 (60.0) 4 (40.0) 0 0 10 (100.0)
DGE 0 0 0 10 (100.0) 0 0 10 (100.0)
Stroma 0 1 (10.0) 4 (40.0) 5 (50.0) 0 7 (70.0) 3 (30.0)
Myometrium 0 1 (10.0) 7 (70.0) 2 (20.0) 0 0 10 (100.0)
FEA Epithelium 12 (50.0) 5 (20.8) 6 (25.0) 1 (4.2) 12 (50.0) 11 (45.8) 1 (4.2)
Stroma 11 (45.8) 2 (8.3) 8 (33.3) 3 (12.5) 11 (45.8) 13 (54.2) 0
Myometrium 4 (16.7) 0 18 (75.0) 2 (8.3) 4 (16.7) 9 (37.5) 11 (45.8)
PR
FS SE 0 1 (7.7) 7 (53.8) 5 (38.5) 0 0 13 (100.0)
SGE 0 1 (7.7) 7 (61.5) 5 (30.8) 0 0 13 (100.0)
DGE 0 2 (15.4) 5 (38.5) 6 (46.2) 0 0 13 (100.0)
Stroma 0 1 (7.7) 10 (76.9) 2 (15.4) 0 10 (76.9) 3 (23.1)
Myometrium 0 5 (38.5) 8 (61.5) 0 0 0 13 (100.0)
LS SE 0 0 5 (50.0) 5 (50.0) 0 1 (10.0) 9 (90.0)
SGE 0 0 5 (50.0) 5 (50.0) 0 1 (10.0) 9 (90.0)
DGE 0 1 (10.0) 3 (30.0) 6 (60.0) 0 1 (10.0) 9 (90.0)
Stroma 4 (40.0) 1 (10.0) 2 (20.0) 3 (30.0) 4 (40.0) 6 (60.0) 0
Myometrium 1 (10.0) 4 (40.0) 3 (30.0) 2 (20.0) 1 (10.0) 2 (20.0) 7 (70.0)
FEA Epithelium 0 1 (4.2) 19 (79.2) 4 (16.7) 0 7 (29.2) 17 (70.8)
Stroma 2 (8.3) 1 (4.2) 19 (79.2) 2 (8.3) 2 (8.3) 21 (87.5) 1 (4.2)
Myometrium 0 4 (16.7) 18 (75.0) 2 (8.3) 0 6 (25.0) 18 (75.0)
SE = surface endometrium; SGE = superficial glandular epithelium; DGE = deep glandular epithelium; FS = follicular stage; LS = luteal stage.). Intensity of
immunolabelling: 1 = weak, 2 =moderate and 3 = strong. Percentage of positive nuclei: 0 = negative (≤5 % positive nuclei); 1 = loss of expression (5-80 % positive
nuclei) and 2 = positive (≥80 % positive nuclei)
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prevailed in both stages, with no differences detected be-
tween the FS and LS (P = 0.363).
Regarding the percentage of positive cells for ER-α, all
the represented endometrial epithelia expressed this
marker during FS (score 2 for all samples; Table 3). A
slight reduction was observed in the percentage of labelled
cells in the SE of LS, but not in the other endometrial epi-
thelia (Table 3); still, the majority of samples retained a
score 2 in the SE of LS, and the differences were non-
significant. In FS, the number of cells ER-α positive in the
endometrial stroma was more heterogeneous than in the
endometrial epithelia, the scores ranging between 1 (5 to80 % of positive nuclei) and 2 (score 2 ≥ 80 % of positive
nuclei). The stromal compartment in LS showed a reduc-
tion in the number of ER-α positive cells as compared to
the FS, but these changes were not significant (P = 0.669).
The myometrium was consistently positive to ER-α ex-
pression, independently of the stage of the cycle (Table 3).
In what regards the ER-α immunoreaction in FEA, a
marked decrease in the intensity and the percentage of
labelled cells was recorded for both the epithelium and
the stromal compartments (Fig. 2c). In FEA, around
70 % of the samples presented a score ≤ 1 for epithelial
ER-α intensity, considerably lower than any epithelia in
either the FS or LS normal endometrium (P ≤ 0.0001;
Fig. 2 ER-α and PR immunohistochemical expression in feline normal and neoplastic endometrium. a. ER-α and b. PR in the LS of cyclic endometrium
are expressed in all uterine layers. BAR = 250 μm c. ER-α expression is decreased in FEA. Transition between positive normal glands and negative
neoplastic cells are notorious. BAR =100 μm. d. PR expression is maintained in FEA. BAR =100 μm. Counterstained with Gill’s haematoxylin
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centage of positive cells to ER-α in the neoplastic epithe-
lium was observed as compared to normal endometrium
epithelia (P ≤ 0.0001): in FEA, half the samples showed
positive nuclei in less than 5 % of the cells, with 45.8 %
of the cases displaying ER-α positive nuclei in less than
80 % of the cells (Table 3). Similarly, a loss in the overall
expression of ER-α, both in intensity of the immunore-
action and the number of cells with positive nuclei, was
observed in FEA stromal compartment compared to the
normal endometrial stroma (P ≤ 0.0001; Table 3). Tu-
mours characterized by myometrial invasion were more
likely to be negative for ER-α in the stromal compart-
ment (P = 0.033). The percentage of ER-α positive
smooth muscle cells in the FEA myometrium was con-
siderably lower than in the normal endometrium (P ≤
0.0001); notwithstanding, the intensity of the ER-α im-
munoreaction did not change between normal endomet-
rium and FEA (P = 0.153).
In general, the intensity of PR immunoreaction was
similar between all the represented endometrial epithelia
(Table 3). In the FS a moderate intensity prevailed over
the strong intensity of immunolabeling, particularly in
the SE and SGE (Table 3). The intensity of immuno-
staining showed a slight increase during the LS in all the
represented epithelia, in particular in the DGE, but these
changes were devoid of significance. The immunoreac-
tion in the stromal compartment was more heteroge-
neous than the observed for ER-α. Higher scores were
recorded in the FS; in LS it was observed a marked loss
in the intensity of immunostaining (P = 0.010; Table 3).Contrasting, lower scores for PR intensity of immuno-
staining were observed in myometrium in FS compared
to LS, but in the latter a wider variation of intensity
scores was obtained. However, the differences among FS
and LS were non-significant for this layer (P = 0.141).
Progesterone receptors were consistently positive in all
evaluated epithelia during the FS; in comparison, a slight
non-significant decrease in the percentage of PR positive
cells was observed in LS (P = 0.435; Table 3). The per-
centage of PR positive cells in the stromal compartment
was higher in the FS than in the LS (P = 0.027; Table 3).
However, score 1 (5 to 80 % of positive nuclei) was the
most prevalent in both stages. A small non-significant
reduction in the percentage of PR positive cells was ob-
served also in myometrium during the LS, compared to
FS (P = 0.070; Table 3).
Compared to the normal endometrium, FEA displayed
more discrete differences in what concerns PR expres-
sion than those presented for ER-α, both at the epithelial
and the stroma compartment (Table 3; Fig. 2d). Feline
endometrial adenocarcinomas epithelium showed a sig-
nificant reduction in either the percentage of PR positive
of cells (P = 0.002) and the intensity of immunolabeling
(P = 0.024). Albeit a small decrease in the intensity and
the percentage of cells with positive nuclei in both FEA
stroma and myometrium compared to normal endomet-
rium, the differences in PR expression in these compart-
ments were devoid of significance (Table 3).
No association between ER-α and PR expression was
found in the epithelial or stromal compartments of nor-
mal or neoplastic endometria. Also, we did not find a
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and the stage of the estrous cycle in FEA.
The proliferative indexes, as estimated by Ki-67 count-
ing, were similar between FS and LS (P > 0.05). In FS,
the proliferative indexes were higher for SGE (16.7 ± 5.4)
as compared to SE and DGE (9.0 ± 2.6 and 7.3 ± 2.8, re-
spectively). In LS, the proliferative indexes were higher
for the glandular epithelia, particularly for the DGE
(21.5 ± 10.0 vs. 13.0 ± 5.2 in SGE), than for the SE (7.1 ±
2.1). Considering the epithelia as a whole, the mean pro-
liferative indexes were 11.0 ± 2.3 and 13.9 ± 3.8 in FS and
LS, respectively. The proliferative index was considerably
higher in the neoplastic epithelium (42.9 ± 3.8) than in
normal endometrial epithelia in FS (95 % CI = 20.9 –
42.9) or LS (95 % CI = 17.3 – 40.8) (Fig. 3). Ki-67 expres-
sion was independent of the tested clinicopathological
features analysed as an indication of tumour aggressive-
ness and of the hormonal receptor status.
Normal feline endometrium presented a CK7+/CK20+
immunoprofile (Fig. 4a-b). The SE presented a strong in-
tensity of immunoreaction against CK7, which did not
change with the stage of the estrous cycle (Table 4). The
intensity of CK7 immunolabeling differed between the
SGE and the DGE, according to the stage of the cycle. A
strong intensity of immunolabelling prevailed in the
SGE and in the DGE in FS, but a decrease in the label-
ling intensity for this molecule was observed in both epi-
thelia during the LS (P = 0.04 and P = 0.039, respectively
for SGE and DGE; Table 4), whereby the most prevalent
intensity of labelling was the moderate. Cytokeratin 7
was consistently detected by all the epithelia represented
in the endometrium, independently of the stage of es-
trous cycle (Table 4).
The stage of the cycle affected the intensity of immu-
noexpression for CK20. The intensity of immunostain-
ing most often recorded in FS was the moderate, the
DGE presenting a slightly increased immunostaining as
compared with the SE and the SGE (Table 4). In LS, a
shift towards stronger intensities was observed in the
SE (P = 0.002) and in the SGE (P = 0.045), but not inFig. 3 Ki-67 immunohistochemical expression in feline endometrium. a. No
cell in metaphase is positive to Ki-67 antigen at the lower bottom. b. FEA a
Gill’s haematoxylinthe DGE (Table 4). As for the percentage of positive
CK20 cells, similar scores were observed in FS and LS,
despite the small non-significant decrease observed in
the surface epithelium in the LS (P = 0.178; Table 4).
In FEA the CK7+/CK20+ epithelial immunoprofile
was maintained (Fig. 4c-d). However, a heterogeneous,
patchy immunolabelling was observed for both CK in
the neoplastic epithelium. A loss in CK7 expression in-
tensity was observed in FEA as compared to the normal
endometrial epithelium (P ≤ 0.0001), whilst the percent-
age of CK7 positive cells remained practically unchanged
(P = 0.065; Table 4). Similarly, CK20 was also lost in FEA
as compared to the normal endometrium, both in terms
of the percentage of positive cells and the intensity of la-
belling (P ≤ 0.0001 and P = 0.01, respectively; Table 4).
No relation was established between CK7 and CK20 sta-
tus in epithelial cells.
The comparison between the immunohistochemical
results and the available clinicopathological data sug-
gested that the myometrial invasion observed in FEA
was associated with negative stromal ER-α status (P =
0.033 and P = 0.006, respectively for percentage of posi-
tive cells and intensity of immunolabelling) and with a
higher percentage of CK20-positive cells (P = 0.033). In
tumours, nuclear atypia was related to a lower intensity
of CK7 labelling (P = 0.026). The loss of PR positive cells
in the myometrium in FEA was related to a higher nu-
clear atypia in carcinoma cells (P = 0.016).
Discussion
Despite the rarity of FEA described in the literature [1–3], a
recent increasing number of reports suggest that the preva-
lence of these tumours may be underestimated [5–8].
Moreover, in one study on uterine tumours in domestic
cats, FEA was the most commonly diagnosed neoplasm
[18]. The selection of cases diagnosed as FEA from the ar-
chives of four different laboratories allowed the use of a lar-
ger series than usual. Its architecture and the histological
features of neoplasic epithelial cells classified the cases
under papillary serous type, the most frequent type of FEArmal endometrium at the LS shows scarcely positive c ells. A positive
re largely positive to Ki-67 antigen. BAR = 50 μm. Counterstained with
Fig. 4 CK7 and CK20 immunohistochemical expression in feline endometrium. a. CK7 is strongly expressed in all epithelia of normal endometrium in
FS. Contrasting, b. CK20 is expressed with a low intensity of labelling. BAR = 250 μm. c. FEA displays a maintenance of CK7+ expression although with
a heterogeneous positivity d. CK20+ immunophenotype in FEA shows a decreased expression and a scarcely, heterogeneous positivity. BAR = 100 μm.
Counterstained with Gill’s haematoxylin
Table 4 Results for the CK 7 and 20 immunolabelling in the epithelial cells from normal feline endometrium (at the FS and LS) and
in FEA
Intensity Percentage of positive cells
n (%) n (%)
Low Moderate High 1 2 3
CK7
FS SE 0 0 13 (100.0) 0 0 13 (100.0)
SGE 0 0 13 (100.0) 0 0 13 (100.0)
DGE 0 2 (15.4) 11 (84.6) 0 0 13 (100.0)
LS SE 0 0 10 (100.0) 0 0 10 (100.0)
SGE 0 7 (70.0) 3 (30.0) 0 0 10 (100.0)
DGE 0 6 (60.0) 4 (40.0) 0 0 10 (100.0)
FEA Epithelium 6 (25.0) 14 (58.3) 4 (16.7) 0 2 (8.3) 22 (91.7)
CK20
FS SE 4 (30.8) 9 (69.2) 0 0 0 13 (100.0)
SGE 2 (15.4) 11 (84.6) 0 0 0 13 (100.0)
DGE 1 (7.7) 10 (76.9) 2 (15.4) 0 0 13 (100.0)
LS SE 0 0 10 (100.0) 0 2 (20.0) 8 (80.0)
SGE 1 (10.0) 5 (50.0) 4 (40.0) 0 0 10 (100.0)
DGE 3 (30.0) 7 (70.0) 0 0 0 10 (100.0)
FEA Epithelium 8 (33.3) 8 (33.3) 8 (33.3) 0 13 (54.2) 11 (45.8)
SE = surface endometrium; SGE = superficial glandular epithelium; DGE = deep glandular epithelium; FS = follicular stage; LS = luteal stage. Intensity of
immunolabelling: 1 = weak, 2 =moderate and 3 = strong
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performed on FEA to gather helpful information regarding
its diagnosis and management, as well as to drive upcoming
areas for study on FEA.
Estrogen receptor alpha and PR expression was found
in epithelial and stromal endometrial compartments and
in myometrium of normal feline uteri. Information on
ER-α and PR expression in normal healthy endometrium
of this species is very limited, and mostly based on the
work of Li et al. (1992) that mimicked the ovarian ste-
roids effects on the feline uterus through the scheduled
administration of exogenous estrogens and progesterone
[39]. However, changes in the intensity of immunostain-
ing of ER-α from FS to LS followed the expected physio-
logical modifications, evidencing a small decrease in the
LS suggestive of the suppressive effect of progesterone
receptor activation. Changes were more notorious in the
surface epithelium and the superficial glandular epithelia
than in deep glandular epithelium; this may be related
with to the increased branching of upper endometrial
glands in FS and to the persistency of proliferation of
basal glands during the LS, that is reflected in the in-
creased coiling reported in this stage [40], which was
supported by data gathered by Ki-67 immunolabeling.
Progesterone receptor expression in epithelial cells
from normal endometrium showed a small decrease
from the FS to LS, following an expectable physiological
pattern. The high heterogeneity of the intensity scores
presented by the different samples might relate to indi-
vidual differences in the moment of the LS or the blood
levels of progesterone, which were not assessed in the
present study. The unavailability of information con-
cerning the normal PR expression in cat endometrium
limits the interpretation of the decrease in the PR stro-
mal expression during LS. However, it is possible that, in
line with other species, stromal and epithelial compart-
ments of the endometrium may respond differently to
steroid hormones [22]. In addition, since endometrial
stroma and epithelium influence each other proliferation
and differentiation [41], differences in either compart-
ment responses to sex steroids may be necessary to the
normal interplay through the uterine cycle.
Recently, a consensus was proposed on the standard
guidelines for hormone receptor assessment using im-
munohistochemistry for canine mammary tumours [42].
However, no guidelines exist for feline mammary or
uterine neoplasms. Consequently, the cases used in the
present study were evaluated on the basis of the results
obtained in controls, using the negative cut-off estab-
lished before for feline mammary tumours and human
endometrial carcinomas [12, 36–38].
All FEA analysed herein lost ER-α immunoexpression
in comparison to the normal endometrium. Moreover,
the tumours were negative for epithelial and for stromalexpression of ER-α (respectively in 50.0 % and 45.8 % of
the samples).
The role of estrogen receptors in the regulation of mam-
malian endometrium, particularly the endometrial prolif-
eration, remains unclear. Uterine proliferation seems to
depend on ER mediated transcription, which may result
from either the ligand ER-α activation (associated to estro-
gen stimulation) or a ligand-independent pathway [43].
Activation of the ER-α drives the transactivation of nu-
merous growth factors, which in turn activate their cog-
nate receptors, leading to multiple signalling cascades
controlling cellular proliferation [44]. Estrogen receptor
alpha may be induced in estrogen-driven tumours, and
tumour growth is often limited by progesterone, once ER
expression is down-regulated by activated PR [44]. How-
ever, proliferation in a tumour may occur driven by the
constitutive activation of a parallel growth factor pathway.
In that case, proliferation would not depend on the pres-
ence of estrogen and progesterone.
Down-regulation of ER-α expression in a variety of tis-
sues has been associated to methylation and to loss of
transcriptional activators [45, 46] or to transdominance
by ER-β which has an anti-proliferative role [13, 47].
These would explain the loss of ER expression and the
acquisition of a hormone resistance status [46], often as-
sociated with high-grade adenocarcinoma developing in
the uterus. Such independence from the sex steroid con-
trol is considered a negative indicator for the clinical
outcome [44].
It was shown that in the endometrium, the loss of ER-
α compromises E2-induced VEGF expression in epithe-
lial cells, shifting VEGF production to stromal cells
thereby inducing stroma-mediated epithelial cell prolif-
eration [48]. Data from the present study suggest that
FEA may enter the category of tumours evolving in the
absence or reduced expression of activated ER-α, thus
highlighting the need to address in future studies the pres-
ence of local growth factors associated to proliferation, in-
cluding IGF-I and VEGF. The proliferative index observed
in neoplastic epithelium is considerably increased com-
pared to normal, healthy endometrial epithelia, supporting
the hypothesis that additional molecules other than the
ER-β are involved in the regulation of the proliferative
pathways in FEA. In the uterus ER-β has been described
as a proliferation controller, while in other organs, such
the mammary gland and the prostate, ER-β plays a pro-
differentiating role [49].
As referred before, a different situation was found con-
cerning PR. Although the tumours also lost PR expres-
sion, this was non-significant in both intensity and
percentage of labelled cells for the stroma, contrary to
the epithelium. Therefore, endometrial cells in FEA re-
tain the ability to respond to progesterone stimulation,
but show a reduced ability to respond to estrogens.
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poorly understood, contrasting to the well-studied hor-
mone status in human endometrial carcinomas. It has
been recently proposed that the expression of PR changes
during tumour progression in endometrial adenocarcin-
oma [50]. Several mechanisms for progesterone inhibition
of endometrial proliferation have been proposed, includ-
ing inhibition of proliferation through opposing the prolif-
erative effects of estrogen in normal endometrium, which
is generally associated with down-regulation of ER-α ac-
tions [50] and up-regulation of ER-β, in a manner that is
progesterone dose-related [51].
Data on sex steroid receptors obtained in the present
study share some resemblance to results from earlier
studies in rabbit endometrial adenocarcinomas. Likewise
cats, rabbits are an induced ovulation species [52], but,
in contrast to cats, rabbits frequently develop endomet-
rial adenocarcinomas, which present two main histo-
logical types: papillary adenocarcinoma and tubular/solid
adenocarcinomas. In that species, papillary adenocarcin-
omas are negative for ER-α and PR [52] and Vinci and
collaborators (2010) concluded that PR expression was
not directly involved in endometrial epithelial carcino-
genesis and that such expression was not of prognostic
value [53]. On the other hand, in women ER and PR
have been established as prognostic markers for endo-
metrial neoplasms [17, 50]. Also, loss of ER-α and PR is
associated with markers of aggressiveness such as age,
myometrial infiltration and lymph node status [37, 50].
Interestingly, in FEA, the negative status for ER-α ex-
pression in the stromal cells was associated with myo-
metrial invasion. Our results suggest that loss of ER-α in
FEA may be related to invasive characteristics of the
tumour, and further strengthen the need for additional
studies on the putative influence of growth factors acting
over the proliferation pathways. In women, it was re-
cently proposed that reduced expression of ER-α and
PR-A, particularly in neoplastic stromal cells, may be of
utmost importance in predicting invasiveness [54]. Add-
itional studies are needed to ascertain this hypothesis in
FEA.
Although in endometrial carcinomas of women, ER
and PR show significant correlation [37, 38], we did not
fund such association in cats. Interestingly, we found
that loss of positive cells for PR in the myometrium of
FEA was related to a higher nuclear atypia in carcinoma
cells. Recently, Tomica et al. (2014) observed lower
levels of PR than ER in the myometrium of high-risk hu-
man endometrial carcinomas [55]. Also, a relation be-
tween cancer cells and the surrounding tissues has been
proposed as a necessary event for endometrial normal
functioning and carcinogenesis [56]. Our results suggest
that myometrial expression of PR may be related to
tumour dedifferentiation and that myometrium maycrosstalk with epithelial and stromal compartments dur-
ing tumour progression.
The expression of hormonal receptors is usually used
in humans to provide important information for adju-
vant hormonal therapy in steroid-responsive tumours. In
women, potential effectiveness of hormonal therapy is
dependent upon the patient selection based on positive
receptor status [57]. Thus, our study sheds light into
whether or not the medical treatment would be of
choice for most animals with endometrial carcinomas.
Nevertheless, it would be of interest to rely on the ex-
pression of sex steroids receptors to predict metastasis
development. We strongly recommend that the hormo-
nal receptor status of FEA should be determined by the
time of histopathological diagnosis.
To the best of our knowledge, this is the first study on
Ki-67 (clone MIB-1) expression in feline cyclic and neo-
plastic endometrium. In normal endometrium, prolifera-
tive indexes were higher in the SGE during the FS, while
in the LS the higher proliferative indices were found in
the DGE. These findings are in agreement with the mor-
phological features that characterize the cycle of glandular
development in the species (respectively the branching of
the upper area of the glands in the FS and the coiling of
the basal glandular area during LS) [40]. In FEA, the pro-
liferative index was remarkably higher than in normal
endometrial epithelia, alike the reported in humans [54].
Ki-67 is widely used to assess proliferative activity. In hu-
man endometrial carcinomas its expression correlates
with the histological grade, depth of myometrium invasion
and risk of carcinoma recurrence [58]. Also in women, Ki-
67 status is inversely related to hormonal receptor status,
particularly in higher grade, ER-α negative, endometrial
carcinomas [37, 38, 50]. In this particular feature, FEA
may be included in the group of endometrial neoplasias
with high proliferation indexes, but with reduced or null
expression of ER-α. As discussed before, this is suggestive
of the existence of alternative pathways controlling the
proliferation in FEA, which needs to be explored in future
studies.
Cytokeratins, the largest group of intermediary fila-
ment proteins, are an important partner in the renewal
and repair of epithelia, by providing rigidity and strength
to cell cytoskeleton, while retaining flexibility [59]. Fur-
ther, CK represent important differentiation markers for
different types of epithelia and epithelial tumours [31].
Particularly, the coordinate expression of CK7 and CK20
defines unique subsets of carcinomas [26]. Different
types of epithelia show specific patterns of CK expres-
sion; CK7 and CK20 are often named as “ductal-type”
keratins [60]. Limited knowledge exists on the normal
pattern of CK7 and CK20 expression in domestic mam-
mal endometrium. The present study showed that
normal endometrial epithelia in cats present a profile
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tensity of immunolabeling remained unchanged for the
surface epithelium, despite the decrease observed in the
intensity of the glandular epithelia immunolabeling. As for
CK20, an increase in the intensity of immunostaining was
observed in the LS. Moreover, the overall expression of
CK7 was higher compared to that of CK20.
Immunohistochemical expression of CK7 and CK20 has
been used in the differentiation of human primary and
metastatic tumours of unknown origin [60–62]. Cytokera-
tin 7 and CK20 are generally confined to epithelia and cell
profile for those CK is largely conserved during malignant
transformation ([60], reviewed by [63]). Cytokeratin 7 and
20 are potentially potent epithelial differentiation and
tumour markers [60] in human and domestic animals.
The association CK7+/CK20- is used in humans to prove
the endometrial origin of tumours [60, 61].
Results from the present study also show that FEA re-
tain a CK7+/CK20+ phenotype, despite the decrease ob-
served in CK7 expression and a more heterogeneous
intensity of labelling on regards to CK20. These findings
corroborate previous reports in smaller case series [32].
Notably, conflicting reports exist on the expression of
CK7 and CK20 in FEA: Miller et al. 2003, described 3/6
and 4/6 positive FEA respectively for CK7 and CK20
[18]. It has been suggested that CK20 may play a role in
facilitating cytoskeleton breakdown and related keratin
filament reorganization [64]. Furthermore, the loss of ex-
pression of CK20 has been associated to cell dedifferenti-
ation [60]. Myometrial invasion and atypia – histological
features commonly associated to invasiveness - were re-
lated to a higher percentage of positive cells for CK20 and
a lower intensity in CK7 labelling, respectively. Cytokera-
tins are also involved in multiple signalling pathways be-
yond their mechanical functions, among epithelial cells or
between the epithelial and mesenchymal compartments
[60]. These widely complex mechanisms may be related to
our findings, but currently we cannot conclude on the pu-
tative role of CK in FEA dedifferentiation and invasive-
ness. Our sample comprised six (25.0 %) animals with
clinical history of mammary gland tumour. One should be
aware of the possibility of uterine metastasis of mammary
gland adenocarcinomas. Moreover, morphological features
of both tumours may be indistinguishable. Unlike primary
FEA, feline mammary gland carcinomas are generally
negative for CK20, maintaining the immunophenotype of
the normal mammary gland in this species [32]. Therefore,
CK20 may be helpful to distinguish between endometrial
primary adenocarcinoma and a metastatic carcinoma in the
uterus, as the pattern of expression of CK20 in different
carcinomas is preserved in metastasis [65]. Altogether,
CK20 might be an important marker for FEA diagnosis in
cases of concomitant mammary carcinomas, since CK7
was previously demonstrated in 50 % of feline mammarygland [32]. The results presented herein confirm the posi-
tivity of FEA for CK7 reported by Espinosa de los Monteros
and co-workers (1999) [32]. Thus, CK7 profile does not
seem valuable in differential diagnosis of FEA and a uterine
metastasis of a mammary gland tumour.Conclusions
Our results show that FEA have a self-hormonal status,
different from that observed in normal endometrium.
Their loss of expression of ER-α in all endometrial com-
partments (epithelium and stroma) as well as in myome-
trium, while retaining PR expression in stroma and
myometrium suggests that epithelial proliferation may
be determined by alternative pathways possibly involving
local growth factors. As expected, proliferative index
assessed by Ki-67 immunoreaction is higher in FEA than
in normal endometrium.
Importantly, CK20 is regarded herein as a potentially
powerful marker for the diagnosis of primary FEA, enab-
ling to differentiate FEA from metastatic disease from
mammary gland. Although other molecular studies are
indicated to support our findings, determination of the
immunohistochemical CK20 profile of uterine tumours
in cats may be of utmost importance in the diagnostic
routine.
In the present study, we highlight the importance of
evaluation both epithelial, stromal and myometrial cells in
neoplastic endometrium, comparing such results with
normal controls. These compartments are likely to re-
spond in a different way to overall hormonal environment
and probably interact with each other. These mechanisms
remain unclear and further studies must be performed to
clarify these hypotheses.
With this study, we have unveiled some of the molecular
events likely involved in feline endometrium carcinogen-
esis. This will certainly ascertain tumour morphological
characterization. Future studies are needed in order to es-
tablish clinical outcome of FEA.
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